Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.90 ▼ -0.26
(-22.55%)
MKT CAP: $138.8M • VOL: 6.14M
52W L $1 52W H $3
ROARABLE / RQD
D- • 36/100
PIOTROSKI
3 / 9
CHRS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$181.1M | -$199.7M | -$215.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $168.0M | $28.5M | -$237.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$138.5M | -$20.4M | -$174.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$138.5M | -$20.4M | -$174.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $88.9M | $126.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $61.0M | -$132.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CHRS.